The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer.Pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) was approved as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer.The FDA based its decision on the randomized phase 3 KEYNOTE-B15/EV-304 trial,…
Source: Healio News
